InflaRx NV Stock Price

0.01 (0.38%)
Upgrade to Real-Time
Afterhours (Closed)


52 Week Range


Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
InflaRx NV IFRX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.01 0.38% 2.66 19:52:21
Open Price Low Price High Price Close Price Prev Close
2.64 2.52 2.68 2.68 2.65
Bid Price Ask Price Spread News
2.53 2.66 0.13 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
536 189,261 $ 2.63 $ 496,841 - 2.42 - 6.88
Last Trade Time Type Quantity Stock Price Currency
19:52:21 formt 1,000 $ 2.66 USD


Draw Mode:

InflaRx NV Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 117.54M 44.19M 39.93M $ - $ - -1.53 -2.00
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - -

more financials information »

InflaRx NV News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical IFRX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.572.732.422.65149,2560.093.5%
1 Month2.983.102.422.78124,770-0.32-10.74%
3 Months3.743.862.423.02243,871-1.08-28.88%
6 Months5.876.382.424.03311,308-3.21-54.68%
1 Year4.996.882.424.43341,978-2.33-46.69%
3 Years33.0053.102.176.15555,195-30.34-91.94%
5 Years15.1953.102.176.65463,881-12.53-82.49%

InflaRx NV Description

InflaRx NV is a clinical-stage biopharmaceutical company that is focused on applying proprietary anti-C5a technology to discover and develop specific inhibitors of the complement activation factor known as C5a. The lead product candidate of the company is IFX-1, which is developed for the treatment of Hidradenitis Suppurativa, a rare and chronic debilitating systemic inflammatory skin disease. The company's proprietary anti-C5a technology is an inflammatory mediator involved in the progression of a variety of autoimmune and other inflammatory diseases. It is also developing IFX-1 for the treatment of AAV, a life-threatening autoimmune disease associated with powerful inflammatory flares that impair kidney function and lead to fatal organ dysfunction.

Your Recent History
InflaRx NV
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.